Floatz logo

Rosuvastatin

Cirrhosis Due to Hepatitis C

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Cirrhosis Due to Hepatitis C cohort.

Asset / SponsorPhaseRating
CARVEDILOL
Tianjin Second People's Hospital
Phase 3B
UMBELLATINE
Tianjin Second People's Hospital
Phase 3B
Ribavirin
Institute of Liver and Biliary Sciences, India
N/AD
Sofosbuvir
Institute of Liver and Biliary Sciences, India
N/AD
Pri-724
Komagome Hospital
Phase 1NR

Same molecule, other indications

Rosuvastatin is also rated in:

inherited lipid metabolism disorderDormant
A
Indicative ·
81 / 100
View asset →
hyperlipidemiaDormant
BBB
Indicative ·
77 / 100
View asset →
cardiovascular disorderDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →